Observing Foam Sclerotherapy Effects on Large Kidney or Liver Cysts in Adults with Polycystic Kidney and Liver Disease

What this Trial Is About

Researchers are studying the effects of foam sclerotherapy on large kidney or liver cysts in patients with autosomal dominant polycystic kidney disease ADPKD and autosomal dominant polycystic liver disease ADPLD. These cysts can cause discomfort and reduce quality of life, and this observational study aims to understand how foam sclerotherapy influences cyst size and patient-reported quality of life over a 12-month period. The study leverages a patient-reported outcome tool approved by the FDA to measure symptom burden in polycystic liver disease. The study observes patients who undergo foam sclerotherapy using 3% Sodium Tetradecyl Sulfate Sotradecol, a treatment currently approved for varicose veins. Patients have 1 to 3 large, non-exophytic cysts causing compressive symptoms, and researchers monitor changes in cyst volume and symptoms. The procedure targets cysts in the liver or kidney, and follow-up visits occur up to 12 months after treatment to assess changes. Participants will be assessed at baseline and then at 1 month, 6 months, and 12 months after treatment. Researchers collect data on pain, quality of life, and health-related quality of life using specialized questionnaires validated for this condition. Organ volumes are measured through imaging to track cyst changes. Patients must comply with follow-up visits, provide informed consent, and the study excludes those who are pregnant or have too many or too small cysts. Overall participation can last over a year to measure the treatments impact.

A Prospective Observational Study of Foam Sclerotherapy .